MEBO Scar found to improve skin hydration, collagen deposition, and elasticity

Ras Al Khaimah (UAE) – Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, has had a groundbreaking paper published in “Advances of Wound Care Journal”, the Official Publication of the Wound Healing Society.

The paper provides fresh insights into the positive effects of Julphar’s ointment, MEBO Scar, in managing scars. MEBO Scar is one of Julphar’s leading products and is made from natural ingredients including sesame, cactus and beeswax, which are thought to improve the appearance of scars.

The study included 45 volunteers, whom were given MEBO Scar as well a widely used anti-scarring topical, which was used as the control for the research. The culmination of three years’ work, found that MEBO Scar improved skin hydration, collagen deposition, and elasticity; things that are vital for scars quality. The research was jointly conducted by Julphar and the University of Manchester in the UK.

“Many topicals promise rapid and effective results but there is limited evidence to support their effectiveness in skin scar management. Cosmetic products were tested on animals up until March 2013, when the European Union prohibited the sale of such products. Aside from the ethical issues surrounding animal testing, the results were not accurate due to the differences between human and animal skin. In addition, in many human skin clinical trials, the evidence is poor.” said Dr. Al Kredly – The Head of Medical Affairs in Julphar.

“We looked at things like hydration, blood flow through the scar, the color of the scar and the amount of collagen, the protein of which scar tissue is composed. What we found was that from the moment the ointment was applied, right up until week 12, there was a significant change in hydration, elasticity, collagen deposition, discoloration, and blood flow which was exactly the kind of evidence we were looking for.” added Dr. Al Kredly.

An overview of the study can be found at the following link: https://www.liebertpub.com/doi/10.1089/wound.2018.0864

-Ends-

About Julphar

Julphar is one of the largest pharmaceutical manufacturers in the Middle East and Africa and for almost four decades, the company has been delivering high quality, innovative and affordable healthcare solutions to families across the globe. Established under the guidance of His Highness Sheikh Saqr Bin Mohammed Al Qasimi in 1980, Julphar employs more than 5,000 people and distributes pharmaceutical products to 50 countries on five continents.

Julphar’s business is centered on three core business units – Julphar Diabetes Solutions, General Medicines and its consumer division, Julphar Life – which target major therapeutic segments including Gastrology, Pain Management, Wound Care, Antibiotics and Cardio-metabolism. Julphar has 16 internationally accredited facilities in Africa, Middle East and Asia that produce more than a million boxes of medicine a day. In 2012, Julphar became one of the largest producers of insulin in the world.

For more information, visit www.julphar.net

For media enquiries, please contact:

Chris Goward

Julphar

T: +971 7 246 1461

M: +971 58 263 3997

E: chris.goward@julphar.net

© Press Release 2019

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.